Changchun high-tech new drug increases indications by drug clinical trial approval
-
Last Update: 2020-06-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Business Agency April 10, the evening of April 9, Changchun High-tech announcement, the company's holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd., polygycol recombinant human growth hormone injection smaller than the fetal age (SGA) new indications application, has been issued by the State Administration of Food and Drug Administration "drug clinical trial approval", Jinsai Pharmaceuticals on April 8, 2014 received the approval of the clinical trial, registered as a biological products for treatmentChangchun Gaoxin said the approved clinical trial of the indications are used for less than the child of child age (SGA) to achieve growth catch-up caused by the small bodyChangchun Gaoxin, a, said that after obtaining approval for the indications clinical trial, the clinical trial should be implemented within 3 years from the date of approval, in accordance with the requirements of the state for clinical trials of such new drugsJinsai Pharmaceuticals has completed Phase I, II and III clinical trials in accordance with the plan, and is tentatively expected to start Phase I clinical studies in 2014The exact completion time of all clinical trials cannot be determined for the time being
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
